Mrinal Patnaik: ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact
Jun 27, 2024, 02:57

Mrinal Patnaik: ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact

Mrinal Patnaik, Physician Scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota, shared a post on X:

ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions.”

Mrinal Patnaik

Source: Mrinal Patnaik/X